Abata Therapeutics Announces First Lead in Development, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis
BOSTON–(BUSINESS WIRE)–Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that it has selected its first development candidate, ABA-101, which has the potential to benefit the 45,000 patients with progressive multiple sclerosis (MS) in the US …